Utilisation of the ESMO-MCBS in practice of HTA.
نویسندگان
چکیده
1Ludwig Boltzmann Institute of Health technology Assessment, Vienna), Austria; 2Independent Pharmaceutical Consultant, Mellieha, Malta; 3Department of Finance, University of Austria, Vienna, Austria; 4Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia; 5Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow,UK; 6Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden; 7Faculty of Medicine Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania; 8Healthcare Improvement Scotland Scottish Medicine Consortium, Glasgow, United Kingdom; 9Agency for Health Technology Assessment and Tariff System, Warsaw, Poland
منابع مشابه
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
BACKGROUND The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a new tool to quantify the clinical benefit that may be anticipated from a novel anticancer treatment. We present here an analysis on the feasibility of the ESMO-MCBS in less frequent tumour entities. METHODS This study evaluates the practicability of the ESMO-MCBS for metastatic neuroendoc...
متن کاملESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies...
متن کاملFive years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
OBJECTIVE Several societies have proposed frameworks to evaluate the benefit of oncology drugs; one prominent tool is the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Our objectives were to investigate the extent of European Medicines Agency (EMA)-approved cancer drugs that meet the threshold for 'meaningful clinical benefit' (MCB), defined by the frame...
متن کاملESMO-Magnitude of Clinical Benefit Scale version 1.1.
Background The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.0 (v1.0) was published in May 2015 and was the first version of a validated and reproducible tool to assess the magnitude of clinical benefit from new cancer therapies. The ESMO-MCBS was designed to be a dynamic tool with planned revisions and updates based upon recognition of expanding needs and shortcomings identifi...
متن کاملDetailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
BACKGROUND The European Society for Medical Oncology (ESMO) has developed the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assess the magnitude of clinical benefit from new cancer therapies. Grading is guided by a dual rule comparing the relative benefit (RB) and the absolute benefit (AB) achieved by the therapy to prespecified threshold values. The ESMO-MCBS v1.0 dual rule e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 27 11 شماره
صفحات -
تاریخ انتشار 2016